Secondary malignancies after hematopoietic stem cell transplantation.
Advances in the field of hematopoietic stem cell transplantation have led to an increasing number of cures of malignant and non-malignant diseases with this therapeutic approach. Long-term survivorship may, however, be associated with secondary malignancies, the result of a complex interaction of treatment-, recipient- and immunosuppression-related factors. Furthermore, the increasing use of donors other than human leukocyte antigen-identical siblings is associated with more intense immunosuppression, delayed immune recovery and higher incidence of B-cell post-transplantation lymphoproliferative disorders. Here, we review the incidence and the risk factors associated with these complications of hematopoietic stem cell transplants.
Ghelani
Dipak
D
Department of Blood and Marrow Transplantation of the University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 423, Houston, TX 77030, USA.
Saliba
Rima
R
Lima
Marcos de
Md
D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects* / Q000379:methods; D015994:Incidence; D009369:Neoplasms / Q000209:etiology* / Q000473:pathology* / Q000503:physiopathology; D012307:Risk Factors; D017741:Survivors; D014019:Tissue Donors